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Background: HPV‐based	cervical	screening	detects	women	at	an	 increased	risk	of	
cervical cancer and precancer. To differentiate among HPV‐positive women those 
with	(pre)cancer,	triage	testing	is	necessary.	The	detection	of	cancer‐associated	host‐
cell	DNA	methylation	 (FAM19A4 and hsa‐mir124‐2)	 in	 cervical	 samples	has	 shown	
valuable as triage test. This multicenter study from 6 collaborating European labora‐
tories and one reference laboratory was set out to determine the intra‐ and inter‐
laboratory agreement of FAM19A4/mir124‐2	DNA	methylation	analysis	utilizing	the	
QIAsure	Methylation	Test.
Methods: Agreement	 analysis	 for	 the	QIAsure	Methylation	 Test	was	 assessed	 on	
high‐risk	HPV‐positive	cervical	specimens	(n	=	1680)	both	at	the	level	of	the	assay	
and	at	the	full	workflow,	including	bisulfite	conversion.
Results: Intra‐	and	inter‐laboratory	assay	agreement	were	91.4%	(534/584;	95%	CI	
88.9‐93.5; κ	=	0.82)	and	92.5%	(369/399;	95%	CI	90.0‐94.7;	κ	=	0.83),	respectively.	
The	inter‐laboratory	workflow	(bisulfite	conversion	and	assay	combined)	agreement	
was	90.0%	(627/697;	95%	CI	87.5%‐92.0%;	κ	=	0.76).
Conclusion: These	data	 show	 that	 the	QIAsure	Methylation	Test	performs	 robust	
and reproducible in different laboratory contexts. These results support the use of 
the	QIAsure	Methylation	Test	for	full	molecular	screening	for	cervical	cancer,	includ‐
ing primary HPV testing and triage testing by methylation analysis.
K E Y W O R D S
cervical	cancer,	cervical	intraepithelial	neoplasia,	host‐cell	DNA	methylation,	HPV,	QIAsure	
methylation test, reproducibility, triage
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1  | INTRODUC TION
HPV‐based cervical screening has a high sensitivity and lower spec‐
ificity	for	cervical	cancer	and	cervical	intraepithelial	neoplasia	(CIN)	
compared to cytology. To improve specificity, triage testing is neces‐
sary. FAM19A4 and hsa‐mir124‐2 methylation analysis in exfoliated 
cervical cell specimens has shown to be a sensitive test for the de‐
tection	of	women	with	cervical	cancer	and	high‐grade	CIN	in	need	of	
treatment.1‐6	The	QIAsure	Methylation	Test	is	an	in	vitro	diagnostic	
assay	comprising	a	multiplex	quantitative	methylation‐specific	PCR	
(qMSP)	that	measures	the	hypermethylation	of	these	two	disease‐
related	genes	(FAM19A4 and hsa‐mir124‐2)	and	the	reference	gene	
ACTB. The test can be used to triage women with a positive HPV 
test, or those with atypical squamous cells of undetermined signif‐
icance	(ASC‐US)	on	cytology,	to	determine	the	need	for	referral	to	
colposcopy or other follow‐up procedures.
The	QIAsure	Methylation	Test	has	reported	a	good	overall	clinical	
performance	for	CIN3	and	cancer	in	high‐risk	(hr)	HPV‐positive	clinician‐
taken	samples	(sensitivity:	67%	for	CIN3	and	100%	for	cancer)	and	self‐
collected	samples	(sensitivity:	66%	for	CIN3	and	100%	for	cancer).1,2,7 
A	key	aspect	 is	the	efficient	detection	of	cervical	carcinomas	and	ad‐
vanced	CIN	lesions,	that	is,	CIN2/3	lesions	associated	with	a	duration	of	
the preceding hrHPV infection of >5 years, which have increased meth‐
ylation	levels	and	many	chromosomal	aberrations	(“cancer‐like”	(epi)ge‐
netic	profile),	and	have	therefore	been	considered	to	have	an	expected	
high	short‐term	risk	of	progression	 to	cancer.3,5,8	A	negative	QIAsure	
Methylation	Test,	on	the	other	hand,	indicates	a	low	cervical	cancer	risk	
over the subsequent 14 years in hrHPV‐positive women.9
From a laboratory perspective, established and consistent clin‐
ical performance must be supported by a good reproducibility of 
the diagnostic assay.10 This is pivotal for quality assurance of the 
diagnostic	workflow	using	the	assay	in	a	cervical	screening	setting.	
For this purpose, one of the objectives of the Valid‐screen project 
was to perform a systematic evaluation of agreement and repro‐
ducibility	related	to	the	QIAsure	Methylation	Test.	The	Valid‐screen	
project is a multicenter, international study designed to validate 
the	clinical	performance	of	the	QIAsure	Methylation	Test	(Horizon	
2020	Programme,	 ID	666800).	For	 reproducibility	 testing,	 a	panel	
of cervical samples derived from different cohorts collected in four 
types of sampling media were tested at six different laboratories 
across Europe and retested in the reference laboratory to determine 
inter‐laboratory agreement. One cohort was tested and retested in 
the reference laboratory to determine intra‐laboratory agreement. 
Here, we report on the intra‐ and inter‐laboratory agreement of the 
QIAsure	Methylation	Test	and	workflow	in	the	Valid‐screen	project.
2  | MATERIAL AND METHODS
2.1 | Study setting
Seven European Union–based national centers and laboratories par‐
ticipated	in	the	Valid‐screen	project	(SME	Instrument	in	the	Horizon	
2020	 Work	 Programme	 of	 the	 European	 Commission	 (666800)):	
University	of	Ljubljana,	Slovenia;	Catalan	institute	of	Oncology,	Spain;	
Klinikum	 Wolfsburg,	 Germany;	 Hvidovre	 Hospital,	 Copenhagen	
University	 Hospital,	 Denmark;	 University	 of	 Edinburgh,	 UK;	 DDL	
Diagnostic	Laboratory,	the	Netherlands;	and	Amsterdam	UMC,	Vrije	
Universiteit	Amsterdam,	Pathology,	Cancer	Center	Amsterdam,	the	
Netherlands.	The	latter	laboratory	served	as	the	reference	laboratory.
2.2 | Study design
Agreement	 analysis	 for	 the	 QIAsure	 Methylation	 Test	 was	 per‐
formed on hrHPV‐positive cervical specimens. Three independent 
agreement measures were completed.
•	 Intra‐laboratory	agreement	of	the	QIAsure	Methylation	Test	was	
determined at the reference laboratory by testing bisulfite‐con‐
verted	 DNA	 from	 584	 cervical	 specimens	 originating	 from	 the	
reference laboratory with subsequent repeat testing of the bisul‐
fite‐converted	DNA.
•	 Inter‐laboratory	 agreement	 was	 determined	 on	 399	 cervical	
specimens obtained from one of the external participating cen‐
ters,	and	bisulfite‐converted	DNA	was	shipped	and	subsequently	
tested in the reference laboratory.
•	 Additionally,	given	that	the	bisulfite	conversion	prior	to	the	meth‐
ylation testing may influence the assay outcome, the full labora‐
tory	workflow	was	analyzed	for	inter‐laboratory	agreement.	For	
this,	each	participating	laboratory	used	DNA	from	cervical	spec‐
imens	 from	 their	 local	 study	 cohort	 (for	 numbers,	 see	 Table	 1)	
and	performed	the	full	workflow.	After	completion	of	the	testing,	
DNA	of	the	analyzed	samples	was	sent	to	the	reference	labora‐
tory for retesting which included the bisulfite conversion step.
For	 precision	 testing,	 a	 control	 sample	 (QSC1)	 was	 incorpo‐
rated into each test run in all the laboratories, including the bisulfite 
conversion.
All	 participating	 partner	 laboratories	 did	 not	 have	 previous	
experience	 with	 qMSP	 but	 underwent	 training	 on	 the	 QIAsure	
Methylation	Test	system	prior	to	the	start	of	study.
2.3 | Specimens
In	total,	1680	hrHPV‐positive	cervical	specimens	were	analyzed	with	
the	 QIAsure	 Methylation	 Test.	 The	 cervical	 specimens	 originated	
from	local	cohorts	organized	by	the	seven	different	European	centers	
and laboratories and collected in concordance with individual national 
or regional requirements, due process of governance, and local ethical 
guidelines.	Details	about	specimen	collection	medium,	handling,	num‐
bers per institute, and study setting are outlined in Table 1. Specimens 
with sufficient leftover material were randomly selected from local 
cohorts.	 It	was	verified	within	each	 test	 situation	 that	 the	QIAsure	
Methylation	Test	positivity	rate	was	comparable	to	the	known	posi‐
tivity rate in an HPV‐positive screening cohort,9 that is, test situation 
1:39%;	test	situation	2:30%;	and	test	situation	3:31%.
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The	 QSC1	 sample	 for	 precision	 testing	 was	 designed	 to	 be	
QIAsure	Methylation	Test	positive	and	consists	of	female	genomic	
DNA	 (Promega)	with	 0.5%	genomic	DNA	 from	 the	 hypermethyla‐
tion‐positive	 cervical	 squamous	 carcinoma	 cell	 line	 SiHa	 (ATCC® 
HTB‐35™).	A	large	batch	of	QSC1	sample	was	prepared	and	tested	
for	performance	 in	 the	QIAsure	Methylation	Test	 in	quadruplicate	
(ie,	mean	and	 standard	deviation	 for	ΔΔCt	values	 for	FAM19A4 of 
8.36 and 0.43 and for mir124‐2	of	7.73	and	0.33,	respectively).	The	
remaining	batch	of	QSC1	sample	was	aliquoted	 in	 an	amount	 suf‐
ficient	for	one	bisulfite	conversion	and	frozen,	to	ensure	that	each	
analysis	started	with	exactly	the	same	DNA	input	with	no	difference	
in	freeze‐thawing	cycles.
2.4 | Histology data
Histology data were obtained from the local registries. Histological 
examination was done locally, and specimens were classified as nor‐
mal	(CIN0),	CIN1,	CIN2,	CIN3,	or	invasive	cancer,	according	to	inter‐
national criteria.11 Of the 399 samples included in inter‐laboratory 
assay	agreement	analysis	(ie,	test	situation	2),	all	had	histology	data	
available.	 Of	 the	 697	 samples	 used	 for	 inter‐laboratory	 workflow	
agreement	analysis	 (ie,	 test	situation	3),	histology	data	were	avail‐
able for 373 specimens.
2.5 | Bisulfite conversion
Bisulfite	conversion	was	performed	with	the	EZ	DNA	Methylation	
kit	 (Zymo	 Research)	 according	 to	 the	 manufacturer's	 specifica‐
tions.	 Standard	 DNA	 input	 for	 bisulfite	 conversion	 was	 250	ng.	
Elution	was	done	with	12.5	µL	M‐elution	buffer	yielding	20	ng/µL	
bisulfite‐converted	DNA.	For	samples	with	insufficient	DNA	yield	
to	accomplish	an	input	of	250	ng	(16%	of	the	samples;	ranging	from	
0%	to	46%	per	laboratory),	a	minimal	input	of	100	ng	was	used.
2.6 | QIAsure methylation test
The	 QIAsure	 Methylation	 Test	 was	 performed	 according	 to	 the	
manufacturer's	 instructions.	 The	QIAsure	Methylation	 Test	 is	 de‐
signed	 and	 manufactured	 by	 Self‐screen	 BV	 (Amsterdam,	 the	
Netherlands),	and	under	an	exclusive	license	distributed	by	QIAGEN	
(Hilden,	 Germany).	 Sample	 input	 in	 the	 assay	 is	 2.5	µL	 bisulfite‐
converted	 DNA.	 The	 assay	 was	 performed	 on	 a	 Rotor‐Gene	 Q	
MDx	 5plex	 HRM	 instrument.	 AssayManager	 software	 (QIAGEN)	
controls amplification as well as data analysis and reporting using 
a	fixed	assay	profile.	The	AssayManager	software	calculates	ΔΔCt	
values for both FAM19A4 and hsa‐mir124‐2. A	sample	is	considered	
“Hypermethylation‐positive”	when	the	ΔΔCt	for	at	least	one	of	the	
targets	 is	below	its	cutoff,	and	“Hypermethylation‐negative”	when	
both	targets	are	above	their	cutoff.	A	sample	 is	considered	 invalid	
when	the	housekeeping	gene	(ACTB)	Ct	value	is	above	its	cutoff.
2.7 | Statistics
For all settings, test results were blinded and concordance analy‐
sis	 was	 not	 performed	 until	 all	 testing	was	 completed.	 Intra‐	 and	
inter‐laboratory	 percent	 of	 agreement,	 95%	 confidence	 bounds,	
and	 Cohen	 kappa	 scores	were	 determined	 for	 samples	with	 valid	
test results from both partner laboratory and reference labora‐
tory.	Interpretation	of	the	kappa	values	was	as	follows:	<0.20:	poor;	
0.21‐0.40: fair; 0.41‐0.60: moderate; 0.61‐0.80: good; and 0.81‐100: 
excellent	agreement.	For	the	QSC1	sample,	the	mean	and	the	stand‐
ard deviation for the ΔΔCt	values	of	the	two	methylation	markers	
were calculated for each laboratory.
3  | RESULTS
3.1 | Intra‐laboratory agreement
DNA	from	a	total	of	584	cervical	specimens	was	bisulfite‐converted	
in	 the	 reference	 laboratory	 and	 analyzed	 twice	with	 the	QIAsure	
Methylation	Test	(ie,	test	situation	1).	The	average	time	between	ini‐
tial	testing	and	repeat	testing	was	165	days	(range	6‐267).	The	intra‐
laboratory	agreement	of	the	QIAsure	Methylation	Test	was	91.4%	
(534/584;	95%	CI	88.9‐93.5)	with	a	κ	=	0.82,	corresponding	with	an	
excellent	agreement	(Table	2).
3.2 | Inter‐laboratory agreement
DNA	 from	 a	 total	 of	 399	 cervical	 specimens	 was	 bisulfite‐con‐
verted	in	laboratory	A	and	analyzed	with	the	QIAsure	Methylation	
Test	(ie,	test	situation	2).	Converted	DNA	was	sent	to	the	reference	
laboratory,	where	the	QIAsure	Methylation	Test	was	repeated.	The	
average time between initial testing and repeat testing was 26 days 
(range	 6‐51).	 The	 inter‐laboratory	 agreement	 of	 the	 QIAsure	
Methylation	Test	was	92.5%	 (369/399;	 95%	CI	90.0‐94.7)	with	 a	
κ	=	0.83,	corresponding	with	an	excellent	agreement	(Table	3).
In	 addition,	 697	 cervical	 specimens	 were	 analyzed	 in	 the	 six	
participating	 laboratories	 and	 unconverted	 DNA	 was	 shipped	 to	
TA B L E  2   Intra‐laboratory	assay	agreement
Reference laboratory result 
2
Reference laboratory result 1
Agreement (95% CI) κHypermethylation‐negative Hypermethylation‐positive Total
Hypermethylation‐negative 329 23 352 91.4%	(88.9‐93.5) 0.82
Hypermethylation‐positive 27 205 232
Total 356 228 584
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the	 reference	 laboratory	 for	 bisulfite	 conversion	 and	 QIAsure	
Methylation	Test	 (ie,	 test	 situation	3).	 The	overall	 inter‐laboratory	
workflow	 agreement	 was	 90.0%	 (627/697;	 95%	 CI	 87.5%‐92.0%)	
with a κ	=	0.76,	corresponding	with	a	good	agreement	(Table	4).
3.3 | Intra‐ and inter‐laboratory precision of the 
control sample
A	total	of	220	measurements	were	available	for	the	control	sample	
QSC1,	ranging	from	12	to	97	measurements	per	laboratory.	Overall,	
the mean and the standard deviation for the ΔΔCt	values	were	8.46	
and 0.49 for FAM19A4, respectively, and 7.90 and 0.80 for hsa‐
mir124‐2,	respectively	(Table	5).
3.4 | Discrepancy analysis
For	intra‐laboratory	assay	agreement,	50	out	of	584	samples	(8.5%)	
had a discrepant test result. For inter‐laboratory assay agreement, 
30	out	of	399	samples	(7.5%)	had	a	discrepant	test	result.	Of	these	
80	samples,	77	(96%)	displayed	ΔΔCt	values	close	to	the	cutoff	of	
the assay on FAM19A4 and/or hsa‐mir124‐2	 (ie,	 within	 one	ΔΔCt	
from	cutoff,	either	in	the	reference	or	in	the	test	laboratory).
For	inter‐laboratory	workflow	agreement,	68	out	of	70	discrepant	
samples	(97%)	displayed	ΔΔCt	values	close	to	the	cutoff	of	the	assay.	
For	the	purpose	of	root	cause	analysis	a	subset	of	these	samples	(n	=	27)	
from which sufficient material was left, the analysis was repeated. This 
resulted	in	15	concordant	results	(56%),	indicating	that	samples	with	a	
value close to the cutoff generate less reproducible results.
3.5 | Histology stratification
The mean ΔΔCt	values	for	the	two	markers	were	calculated	for	the	
different	histology	grades	(whenever	histology	data	were	available).	
Looking	at	the	full	workflow,	the	methylation	levels	increased	with	
disease severity, resulting in the lowest mean ΔΔCt	values	for	can‐
cer: 7.2 for FAM19A4 and 6.7 for hsa‐mir124‐2; and the highest mean 
ΔΔCt	 values	 for	 samples	 with	 no	 (evidence	 of)	 disease:	 13.0	 for	
FAM19A4 and 10.4 for hsa‐mir124‐2	(Table	6).	Samples	with	CIN1	or	
CIN2	were	in	the	middle	of	the	spectrum	and	closer	to	the	assay	cut‐
off.	Cancer	cases,	CIN3,	and	normal	samples	were	at	the	outer	ends	
of	 the	 spectrum	 and	 showed	 highest	 agreement	 values	 of	 100%,	
95%,	and	92%,	respectively	(Table	7).	For	sole	QIAsure	Methylation	
Test data, a similar trend was observed, although less pronounced 
(Table	7).
4  | DISCUSSION
We evaluated the intra‐ and inter‐laboratory agreement of 
FAM19A4/mir124‐2	DNA	methylation	analysis	utilizing	the	QIAsure	
Methylation	Test,	both	at	the	level	of	the	assay	and	at	the	full	work‐
flow	(including	bisulfite	conversion),	supported	through	a	collabora‐
tion across six different European test laboratories and a reference 
laboratory.	To	the	best	of	our	knowledge,	this	is	the	first	systematic	
and international assessment of inter‐laboratory reproducibility of 
a	CE‐IVD	qMSP	assay	for	DNA	hypermethylation	detection.	Good‐
to‐excellent intra‐ and inter‐laboratory agreement of the assay and 
the	 full	workflow	were	observed	 (ie,	 kappa	value	 range	 from	0.76	
to	0.83).
The	present	study	confirms	that	the	QIAsure	Methylation	Test	
is	a	reproducible	test,	which	is	a	key	parameter	when	considering	
its application in cervical screening. When applying the minimal 
intra‐ and inter‐laboratory reproducibility criteria from the guide‐
lines	 for	primary	HPV	DNA	test	 requirements,12 the lower confi‐
dence	bound	for	agreement	and	kappa	value	in	this	study	are	above	
the	 threshold	 of	 87%	 and	 0.5,	 respectively,	 for	 intra‐laboratory	
TA B L E  3   Inter‐laboratory	assay	agreement
Test laboratory A
Reference laboratory
Agreement (95% CI) κHypermethylation‐negative Hypermethylation‐positive Total
Hypermethylation‐negative 251 5 256 92.5%	(90.0‐94.7) 0.83
Hypermethylation‐positive 25 118 143
Total 276 123 399
TA B L E  4   Inter‐laboratory	workflowa agreement
Test laboratoryb
Reference laboratory
Agreement (95% CI) κHypermethylation‐negative Hypermethylation‐positive Total
Hypermethylation‐negative 456 45 501 90.0%	(87.5‐92.0) 0.76
Hypermethylation‐positive 25 171 196
Total 481 216 697
aResult	following	bisulfite	conversion	and	QIAsure	Methylation	Test	
bPooled data from the six European laboratories 
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assay analysis, inter‐laboratory assay analysis, and inter‐laboratory 
workflow	analysis.	Although	these	minimal	intra‐	and	inter‐labora‐
tory	reproducibility	thresholds	have	been	set	for	HPV	DNA	tests,12 
and	may	not	directly	be	applied	to	other	molecular	markers	(such	as	
methylation	markers),	the	QIAsure	Methylation	Test	complies	with	
the criteria, supporting robustness of the assay.
After	 stratification	 for	 histology,	 agreement	 was	 the	 highest	
among	 women	 with	 cancer	 (100%,	 3/3),	 followed	 by	 CIN3	 (95%,	
39/41;	 and	96%,	72/75)	 and	normal	histology	 (92%,	206/225;	 and	
93%,	149/161).	This	represents	true‐positive	and	true‐negative	sam‐
ple	groups	characterized	by	methylation	levels	most	distanced	from	
the	 assay	 cutoff.	 Discordance	 in	 test	 outcome	was	 predominantly	
associated with methylation levels around the assay cutoff, which is 
known	 to	be	prone	 to	variation,	 and	 this	observation	 is	 consistent	
with other studies using diagnostic assays with binary output.13,14
Of note, the participating test laboratories did not have pre‐
vious experience with methylation testing and many practical 
variables	 were	 included	 (Table	 1),	 that	 is,	 seven	 different	 lab‐
oratories from six different countries, four types of collection 
media,	 six	 different	 DNA	 extraction	methods,	 and	 assay	 com‐
parison with or without the bisulfite conversion. The high agree‐
ment	 values	 therefore	 indicate	 that	 the	 QIAsure	 Methylation	
Test	and	workflow	are	resilient	to	the	vagaries	of	different	lab‐
oratory	and	service	contexts.	A	 limitation	of	 the	study	may	be	
that its design does not allow for clinical performance evalua‐
tion	of	the	QIAsure	Methylation	Test.	External	clinical	validation	
of	the	QIAsure	Methylation	Test	is	the	topic	of	a	large	ongoing	
study.	 Because	 the	QIAsure	Methylation	 Test	 is	 an	 innovative	
assay, there are no published reproducibility data of comparable 
assays.	As	a	consequence,	results	cannot	be	compared	to	similar	
assays nor be related to standard guidelines. When comparing 
the	 agreement	 of	 the	QIAsure	Methylation	 Test	 to	 other	HPV	
triage	 assays,	 like	 cytology	 (κ	=	0.46)15 or p16/Ki67 dual‐stain 
cytology	 (κ	=	0.71),16 a higher agreement is observed for the 
QIAsure	Methylation	Test.
In	conclusion,	the	QIAsure	Methylation	Test	 is	a	highly	repro‐
ducible assay and may be used to discern hrHPV‐positive women 
with clinically relevant cervical disease. These results support the 
possibility and feasibility of a full molecular screening for cervical 
cancer, including primary HPV testing and triage by methylation 
analysis.
Laboratory N=
ΔΔCt FAM19A4 ΔΔCt hsa‐mir124‐2
Mean Std dev Mean Std dev
Reference laboratory 97 8.51 0.48 7.85 0.61
Laboratory	A 43 8.63 0.41 8.31 0.65
Laboratory B 13 8.26 0.47 7.34 0.59
Laboratory	C 12 8.07 0.47 7.66 0.83
Laboratory	D 16 8.38 0.54 8.44 1.45
Laboratory E 19 8.72 0.35 8.36 0.35
Laboratory F 20 7.97 0.20 6.91 0.31
Total 220 8.46 0.49 7.90 0.80
TA B L E  5   Inter‐laboratory	precision.	
Reported are the number of 
measurements, the mean, and standard 
deviations	for	the	control	sample	QSC1
TA B L E  6  Mean	ΔΔCt	values	stratified	for	histology
Histology
Mean ΔΔCt 
FAM19A4
Mean ΔΔCt 
hsa‐mir124‐2
Cancer	(n	=	3) 7.2 6.7
CIN3	(n	=	41) 9.8 8.0
CIN2	(n	=	51) 12.2 9.2
CIN1	(n	=	53) 12.6 10.1
Normal	or	no	evidence	of	
CIN	(n	=	225)
13.0 10.4
TA B L E  7   Inter‐laboratory	assay	and	workflow	agreement	stratified	for	histology
Histology
Full workflow QIAsure methylation test
Total
Number discrepant 
results Agreement Total
Number discrepant 
results Agreement
Cancer 3 0 100% 3 0 100%
CIN3 41 2 95% 75 3 96%
CIN2 51 7 86% 75 8 89%
CIN1 53 9 83% 85 7 92%
Normal	or	no	evidence	of	CIN 225 19 92% 161 12 93%
Total 373 37 90% 399 30 92%
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